Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. ViewRay sets $52m IPO terms
ViewRay set the terms for its pending initial public offering, saying it plans to float 4 million shares at $12 to $14 apiece.
At the midpoint of the range, the MRI-guided radiation therapy maker’s IPO would fetch $52 million. Read more
2. Bard’s Medafor wins injunction against CryoLife’s PerClot Topical
C.R. Bard won a preliminary injunction barring U.S. sales of CryoLife’s PerClot Topical hemostasis agent in a patent infringement lawsuit in Delaware.
Atlanta-based CryoLife last year asked Judge Susan Robinson of the U.S. District Court for Delaware to rule that the PerClot product does not infringe a patent for Bard subsidiary Medafor’s Arista. Medafor filed a counter-claim for infringement and asked Robinson for the preliminary injunction. Read more
1. St. Jude Medical pushes ‘play’ on Portico TAVI device
St. Jude Medical, which paused implantations of its Portico replacement heart valve last fall out of an abundance of caution, told MassDevice.com that European authorities reinstated Portico’s CE Mark.
The decision means St. Jude is resuming clinical and commercial implants of the Portico 23mm and 25mm transcatheter aortic valve implants in Europe, spokesman Justin Paquette told us via email. Read more